Can a diabetes drug boost heart function in obese patients?
NCT ID NCT06782139
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests whether enavogliflozin, a diabetes drug, can improve heart function and exercise capacity in 30 obese adults with type 2 diabetes. Participants receive either the drug or a placebo for 12 weeks, and doctors measure changes in heart blood flow and fitness. The goal is to see if the drug helps the heart work better in this high-risk group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Enavogliflozin (a drug that lowers blood sugar and may help the heart)
What this could lead to
If it works, this could show that enavogliflozin improves heart function and exercise ability in people with obesity and diabetes.
What could go wrong
This is a small, early-phase trial with only 30 people, so results may not apply to everyone. The drug may not show clear benefits over placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Korea University Anam Hospital
RECRUITINGSeoul, 02841, South Korea
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact